ICU Medical, Inc. (ICUI)
NASDAQ: ICUI · Real-Time Price · USD
121.11
-1.74 (-1.42%)
At close: Apr 28, 2026, 4:00 PM EDT
121.01
-0.10 (-0.08%)
After-hours: Apr 28, 2026, 5:09 PM EDT
ICU Medical Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for ICU Medical stock have an average target of 169, with a low estimate of 163 and a high estimate of 180. The average target predicts an increase of 39.54% from the current stock price of 121.11.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ICU Medical stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 1 | 1 | 1 |
| Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 5 | 5 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Keybanc | Keybanc | Buy Maintains $180 → $164 | Buy | Maintains | $180 → $164 | +35.41% | Apr 27, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $178 → $163 | Buy | Maintains | $178 → $163 | +34.59% | Apr 17, 2026 |
| Keybanc | Keybanc | Buy Maintains $175 → $180 | Buy | Maintains | $175 → $180 | +48.63% | Feb 20, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $172 → $178 | Buy | Maintains | $172 → $178 | +46.97% | Feb 20, 2026 |
| Keybanc | Keybanc | Buy Maintains $173 → $175 | Buy | Maintains | $173 → $175 | +44.50% | Nov 7, 2025 |
Financial Forecast
Revenue This Year
2.22B
from 2.23B
Decreased by -0.50%
Revenue Next Year
2.32B
from 2.22B
Increased by 4.46%
EPS This Year
8.27
from 0.03
Increased by 27,750.39%
EPS Next Year
9.39
from 8.27
Increased by 13.45%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 2.3B | 2.4B | |||
| Avg | 2.2B | 2.3B | |||
| Low | 2.1B | 2.2B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 3.8% | 9.1% | |||
| Avg | -0.5% | 4.5% | |||
| Low | -5.3% | -1.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 8.59 | 10.13 | |||
| Avg | 8.27 | 9.39 | |||
| Low | 7.89 | 8.62 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 28,812.4% | 22.5% | |||
| Avg | 27,750.4% | 13.5% | |||
| Low | 26,456.0% | 4.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.